<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04574115</url>
  </required_header>
  <id_info>
    <org_study_id>Omega Refractive Capsule VI</org_study_id>
    <nct_id>NCT04574115</nct_id>
  </id_info>
  <brief_title>Clinical Investigation of Omega Refractive Capsule, Model VI</brief_title>
  <acronym>ORCVI</acronym>
  <official_title>Clinical Investigation of Omega Refractive Capsule, Model VI in Combination With a Commercially Available, FDA Approved Monofocal or Toric Intraocular Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omega Ophthalmics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Omega Ophthalmics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and effectiveness of the&#xD;
      investigational Omega Refractive Capsule (model VI)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, interventional, randomized, controlled, paired eye,&#xD;
      subject-masked design.&#xD;
&#xD;
      Subjects will be randomly assigned to which eye will receive the Omega Refractive capsule VI&#xD;
      with an FDA approved intraocular lens. Fellow eyes will serve as controls and receive an FDA&#xD;
      approved IOL (no Omega capsule).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 6, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study is a prospective, interventional, randomized, controlled, paired eye, subject-masked design.&#xD;
Subjects will be randomly assigned to which eye will receive the Omega Refractive capsule VI with an FDA approved intraocular lens. Fellow eyes will serve as controls and receive an FDA approved IOL (no Omega capsule).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>subject masked to treatment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of fusion of peripheral anterior and posterior capsule</measure>
    <time_frame>6 Month Postoperative Visit</time_frame>
    <description>slit lamp exam assessment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Study Eye</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>study eye will receive the Omega Refractive capsule VI with an FDA approved intraocular lens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Eye</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fellow eyes will serve as controls and receive an FDA approved IOL (no Omega capsule).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Omega Refractive Capsule with an FDA approved Intraocular Lens</intervention_name>
    <description>Omega refractive capsule in conjunction with an FDA approved Intraocular Lens</description>
    <arm_group_label>Study Eye</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FDA approved Intraocular Lens</intervention_name>
    <description>FDA approved Intraocular Lens</description>
    <arm_group_label>Control Eye</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  40 years of age or older at the time of surgery diagnosed with bilateral cataracts&#xD;
&#xD;
          -  Able to understand and sign an informed consent&#xD;
&#xD;
          -  Willing and able to complete all study visits and assessments required for the study&#xD;
&#xD;
          -  Calculated lens power within the available range&#xD;
&#xD;
          -  Corrected distance visual acuity is equal to or worse than 20/40 in each eye with or&#xD;
             without a glare source present&#xD;
&#xD;
          -  Bilateral cataracts eligible for extraction by phacoemulsification and capsular bag&#xD;
             fixated IOL implantation&#xD;
&#xD;
          -  Potential postop visual acuity of 20/25 or better in the judgment of the surgeon&#xD;
&#xD;
          -  Preoperative corneal astigmatism of 4.0 D or less with normal corneal topography&#xD;
&#xD;
          -  Clear intraocular media other than cataract&#xD;
&#xD;
          -  Preop endothelial cell density of 2000 cells/mm2 or more&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject's best corrected vision is light perception or no light perception in either&#xD;
             eye&#xD;
&#xD;
          -  Cataract opacification preventing adequate Binocular Indirect Ophthalmoscopic retinal&#xD;
             and macular examination.&#xD;
&#xD;
          -  Orbital abnormalities, such as thyroid related orbitopathy, causing significant&#xD;
             exophthalmos.&#xD;
&#xD;
          -  Eyelid abnormalities causing lagophthalmos.&#xD;
&#xD;
          -  Significant anterior blepharitis or meibomian gland dysfunction&#xD;
&#xD;
          -  Corneal abnormalities or conditions, other than regular topographic corneal&#xD;
             astigmatism&#xD;
&#xD;
          -  Krukenburg's spindle (linear pigmentary deposits on the corneal endothelium)&#xD;
&#xD;
          -  Abnormalities of the iris including trans-illumination defects&#xD;
&#xD;
          -  Pupil abnormalities (abnormally shaped, fixed or non-reactive)&#xD;
&#xD;
          -  Pharmacologic dilation less than 7 mm&#xD;
&#xD;
          -  Axial length &lt;22.5mm&#xD;
&#xD;
          -  Lens thickness &lt;4.1 mm&#xD;
&#xD;
          -  Anterior chamber depth &lt;2.5mm&#xD;
&#xD;
          -  Prior ocular surgery&#xD;
&#xD;
          -  Epiretinal membrane&#xD;
&#xD;
          -  Macular edema&#xD;
&#xD;
          -  Retinal tears including operculated holes&#xD;
&#xD;
          -  Amblyopia&#xD;
&#xD;
          -  Glaucoma of any kind&#xD;
&#xD;
          -  Pseudoexfoliation syndrome&#xD;
&#xD;
          -  History of uveitis/iritis&#xD;
&#xD;
          -  Diabetic retinopathy&#xD;
&#xD;
          -  Acute, chronic or uncontrolled systemic or ocular disease that may confound the&#xD;
             results of the study (including rheumatologic conditions such as Rheumatoid arthritis,&#xD;
             ankylosing spondyliltis, Sjögren's syndrome, and neurologic conditions such as optic&#xD;
             neuritis or multiple sclerosis).&#xD;
&#xD;
          -  Prior or anticipated use of tamsulosin or silodosin (e.g., Flomax®, Flomaxtra®,&#xD;
             Rapaflo®) or similar medications&#xD;
&#xD;
          -  Average Keratometry &lt;38D or &gt; 48D by topography&#xD;
&#xD;
          -  Any pathology of the zonules including evidence of zonular weakness, zonular&#xD;
             instability, zonular damage, or coloboma effecting zonules.&#xD;
&#xD;
          -  History of ocular trauma&#xD;
&#xD;
          -  Pregnant, lactating, or has another condition with associated fluctuation of hormones&#xD;
             that could lead to refractive changes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Orlich, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Clinica 20/20</name>
      <address>
        <city>San José</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Costa Rica</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>March 7, 2021</last_update_submitted>
  <last_update_submitted_qc>March 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

